---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-021208"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2026-06-19T00:58:01+00:00"
generated_at: "2026-06-22T10:08:03.375530+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CervoMed prices $10M registered direct offering of 2.5M shares at $4.00/share

## Summary
- 2,500,000 shares at $4.00 per share for gross proceeds of $10M.
- Closing expected on or about June 22, 2026; H.C. Wainwright as placement agent.
- Net proceeds for working capital and general corporate purposes.
- 30-day lock-up on further equity issuances; 6-month ban on variable rate transactions.
- Placement agent gets 6% cash fee and 5-year warrants exercisable at $5.00/share.

## SEC filing metadata
- accession: 0001437749-26-021208
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2026-06-19T00:58:01+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774926021208/0001437749-26-021208-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774926021208/crvo20260618_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-021208
- JSON: https://secwatch.observer/filing/0001437749-26-021208.json
- Plain text: https://secwatch.observer/filing/0001437749-26-021208.txt

## Key facts
- Material Agreements
  CervoMed Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2026-06-16).
  - Action: entry
  - Counterparty: H.C. Wainwright & Co., LLC
  - Effective: 2026-06-16
  source text: On June 16, 2026, the Company entered into an engagement letter, in connection with the Offering (the “Engagement Letter”), with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774926021208/0001437749-26-021208-index.htm
- Material Agreements
  CervoMed Inc. entered into Securities Purchase Agreement valued at $10.0 million (effective 2026-06-18).
  - Action: entry
  - Agreement: equity purchase
  - Value: $10.0 million
  - Effective: 2026-06-18
  source text: On June 18, 2026, CervoMed Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), 2,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $4.00 per Share, for aggregate gross proceeds of $10.0 million, before deducting placement agent fees (as described in greater detail below) and related offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1053691/000143774926021208/0001437749-26-021208-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.